# Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

> **NCT07282743** · PHASE2 · RECRUITING · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 285 (estimated)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** GL0034 Dose Level 1
- **DRUG:** GL0034 Dose Level 2
- **DRUG:** GL0034 Dose Level 3
- **DRUG:** GL0034 Dose Level 4
- **DRUG:** GL0034 Dose Level 5
- **DRUG:** GL0034 Dose Level 6
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07282743
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-20
- **Primary completion:** 2027-04
- **Final completion:** 2027-08
- **Target enrollment:** 285 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07282743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07282743, "Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07282743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*